title: [Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotection through a nitric oxide-dependent mechanism].
abstract: OBJECTIVE
  Alpha-human atrial natriuretic peptide (alpha-hANP) has been used to treat patients with heart failure due to its natriuretic and vasodilatory activities. Recent reports have suggested that alpha-hANP generates nitric oxide (NO) that is known to be involved in myoprotective mechanisms. In this study, the effects of preischemic infusion of alpha-hANP against reperfusion injury were evaluated.
  
  
  METHODS
  Isolated rat (Sprague-Dawley rat, age 8-10 weeks, weight 260-340 g) hearts were subjected to Langendorff perfusion with buffered Krebs-Henseleit solution and were divided into three groups: Six hearts were treated with 0.1 microM of alpha-hANP for 10 min (Group H), six hearts with 1 mM of a NO synthetase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) for 5 min before alpha-hANP (Group L), and six hearts served as the controls with no interventions (Group C). All groups were then subjected to 20 min of global ischemia followed by 120 min of reperfusion. Left ventricular pressures and coronary flow were measured throughout the experiment and infarct size was evaluated at the end of the experiments.
  
  
  RESULTS
  Treatment with alpha-hANP significantly reduced infarct size as compared to control hearts whereas pretreatment with L-NAME almost reversed the preventive effect (Group C = 42.7 +/- 2.3%, Group H = 26.1 +/- 2.8% *, Group L = 39.0 +/- 1.6%; * p < 0.01 vs Group C). There were no significant differences in left ventricular pressure and coronary flow between the three groups.
  
  
  CONCLUSIONS
  Preischemic infusion of alpha-hANP may provide myoprotective effects against postischemic reperfusion, possibly through a NO-dependent mechanism.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Osaka Medical College, Daigakucho 2-7, Takatsuki, Osaka 569-8686.
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Okawa
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Horimoto
authors.forename: Shigetoshi
authors.initials: S
authors.lastname: Mieno
authors.forename: Yukiya
authors.initials: Y
authors.lastname: Nomura
authors.forename: Kenichi
authors.initials: K
authors.lastname: Nakahara
authors.forename: Masataka
authors.initials: M
authors.lastname: Yoshida
authors.forename: Kunio
authors.initials: K
authors.lastname: Asada
authors.forename: Shinjiro
authors.initials: S
authors.lastname: Sasaki
mesh_terms: D000818:Animals; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000494:pharmacology*; D019157:Ischemic Preconditioning, Myocardial; D008297:Male; D009203:Myocardial Infarction / Q000503:physiopathology; D015425:Myocardial Reperfusion; D009569:Nitric Oxide / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D009569:Nitric Oxide; D009320:Atrial Natriuretic Factor